OBJECTIVE: The role of antidepressants in treating bipolar disorder is controversial, and the comparative effectiveness of specific drugs is insufficiently studied.We report here a comparison of monoamine oxidase inhibitors (MAOIs) with the serotonin reuptake inhibitor paroxetine (PAROX). EXPERIMENTAL DESIGN: We conducted a retrospective analysis of data from a larger study, using the first antidepressant trial administered either after entry (n = 46) or after a recurrent episode during study participation (n = 6).Twenty two patients were treated with PAROX and 30 with an MAOI. Durable recovery was determined from Hamilton depression and Young mania scores, based on published criteria. PRINCIPAL OBSERVATIONS: PAROX treatment led to durable recovery in 27% of patients, a result very similar to the 24% recovery rate found in a recent STEP-BD trial. In contrast, patients treated with an MAOI had a 53% durable recovery rate. Survival analysis showed a significantly faster onset of durable recovery with MAOIs (x2 = 4.77, p = 0.029). Among subjects who were able to complete an adequate treatment trial of at least four weeks duration, durable recovery was attained in a significantly greater proportion of those treated with an MAOI (16 of 23, 70%) as compared to PAROX (6 of 18, 33%)(Fisher's Exact Test, p = 0.023). CONCLUSIONS: In these patients with bipolar depression, the antidepressant effectiveness of PAROX was unacceptably low, but rates of recovery with MAOIs were significantly higher.
OBJECTIVE: The role of antidepressants in treating bipolar disorder is controversial, and the comparative effectiveness of specific drugs is insufficiently studied.We report here a comparison of monoamine oxidase inhibitors (MAOIs) with the serotonin reuptake inhibitor paroxetine (PAROX). EXPERIMENTAL DESIGN: We conducted a retrospective analysis of data from a larger study, using the first antidepressant trial administered either after entry (n = 46) or after a recurrent episode during study participation (n = 6).Twenty two patients were treated with PAROX and 30 with an MAOI. Durable recovery was determined from Hamilton depression and Young mania scores, based on published criteria. PRINCIPAL OBSERVATIONS: PAROX treatment led to durable recovery in 27% of patients, a result very similar to the 24% recovery rate found in a recent STEP-BD trial. In contrast, patients treated with an MAOI had a 53% durable recovery rate. Survival analysis showed a significantly faster onset of durable recovery with MAOIs (x2 = 4.77, p = 0.029). Among subjects who were able to complete an adequate treatment trial of at least four weeks duration, durable recovery was attained in a significantly greater proportion of those treated with an MAOI (16 of 23, 70%) as compared to PAROX (6 of 18, 33%)(Fisher's Exact Test, p = 0.023). CONCLUSIONS: In these patients with bipolar depression, the antidepressant effectiveness of PAROX was unacceptably low, but rates of recovery with MAOIs were significantly higher.
Authors: Ellen Frank; David J Kupfer; Michael E Thase; Alan G Mallinger; Holly A Swartz; Andrea M Fagiolini; Victoria Grochocinski; Patricia Houck; John Scott; Wesley Thompson; Timothy Monk Journal: Arch Gen Psychiatry Date: 2005-09
Authors: W A Nolen; R W Kupka; G Hellemann; M A Frye; L L Altshuler; G S Leverich; T Suppes; P E Keck; S McElroy; H Grunze; J Mintz; R M Post Journal: Acta Psychiatr Scand Date: 2007-05 Impact factor: 6.392
Authors: Gary S Sachs; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Stephen R Wisniewski; Laszlo Gyulai; Edward S Friedman; Charles L Bowden; Mark D Fossey; Michael J Ostacher; Terence A Ketter; Jayendra Patel; Peter Hauser; Daniel Rapport; James M Martinez; Michael H Allen; David J Miklowitz; Michael W Otto; Ellen B Dennehy; Michael E Thase Journal: N Engl J Med Date: 2007-03-28 Impact factor: 91.245
Authors: Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11 Impact factor: 5.270
Authors: Adam Stewart; Siddharth Gaikwad; Evan Kyzar; Jeremy Green; Andrew Roth; Allan V Kalueff Journal: Neuropharmacology Date: 2011-08-09 Impact factor: 5.250
Authors: Jonathan Savitz; Sheldon Preskorn; T Kent Teague; Douglas Drevets; William Yates; Wayne Drevets Journal: BMJ Open Date: 2012-02-22 Impact factor: 2.692